But today it has announced FDA approval for Tygacil, a new antibiotic that may be very useful at treating infections where there are multiple types of resistant bacteria, or where the pathogen can't be identified.
When it comes in contact with single-celled pathogens, such as viruses or parasites or bacteria, it disables the pathogens' metabolic enzymes, causing the pathogen to suffocate and die.